DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer

Anticancer Research

Volumn 29, Issue 7, 2009, Pages 2753-2757

  Yamashita, Shin Ichi ^a   Chujo, Masao ^a   Moroga, Toshihiko ^a   Anami, Kentaro ^a   Tokuishi, Keita ^a   Miyawaki, Michiyo ^a   Kawano, Yozo ^a   Takeno, Shinsuke ^a   Yamamoto, Satoshi ^a   Kawahara, Katsunobu ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Chemotherapy; DYRK2; Lung cancer; p53; Predictive marker

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CARBOPLATIN; CISPLATIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; NAVELBINE; OXONATE POTASSIUM; PACLITAXEL; UFT;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE MARKER; DYRK2 GENE; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT RESPONSE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 69249197862     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717, 1997. (Pubitemid 27260107)
2. Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, Whitehead M, Zhu CQ, Livingston R, Johnson DH, Rigas J, Seymour L, Winton T and Shepherd FA: Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non-small cell lung cancer. J Clin Oncol 25: 5240-5247, 2007. (Pubitemid 350232256)
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92-98, 2002.
4. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M and Johnson D: Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18: 623-631, 2000. (Pubitemid 30078543)
5. Hotta K, Fujiwara Y, Matsuo K, Suzuki T, Kiura K, Tabata M, Takigawa N, Ueoka H and Tanimoto M: Recent improvement in the survival of patients with advanced non-small cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Cancer 109: 939-948, 2007. (Pubitemid 46333536)
6. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T and Soria JC; IALT Bio Investigators: DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991, 2006. (Pubitemid 44343542)
7. Mimori K, Sadanaga N, Yoshikawa Y, Ishikawa K, Hashimoto M, Tanaka F, Sasaki A, Inoue H, Sugimachi K and Mori M: Reduced tau expression in gastric cancer can identify candidates for successful paclitaxel treatment. Br J Cancer 94: 1894-1897, 2006.
8. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF and Pusztai L: Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102: 8315-8320, 2005. (Pubitemid 40800086)
9. Anelli A, Brentani RR, Gadelha AP, Amorim De Albuquerque A and Soares F: Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer. Ann Oncol 14: 428-432, 2003. (Pubitemid 36367421)
10. Miller CT, Aggarwal S, Lin TK, Dagenais SL, Contreras JI, Orringer MB, Glover TW, Beer DG and Lin L: Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas. Cancer Res 63: 4136-4143, 2003. (Pubitemid 36917938)
11. Taira N, Nihira K, Yamaguchi T, Miki Y and Yoshida K: DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell 25: 794-796, 2007. (Pubitemid 46341924)
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
13. Ardavanis A, Koumna S, Fragos I, Malliou S, Kyriakou F, Mantzaris I, Scorilas A and Rigatos G: Erlotinib monotherapy in patients with advanced non-small cell lung cancer: an effective approach with low toxicity. Anticancer Res 28: 2409-2415, 2008.
14. Pothos A, Plastira K, Plastiras A, Vlachodimitropoulos D, Goutas N and Angelopoulou R: Comparison of chromogenic in situ hybridisation with fluorescence in situ hybridisation and immunohistochemistry for the assessment of her-2/neu oncogene in archival material of breast carcinoma. Acta Histochem Cytochem 41: 59-64, 2008. (Pubitemid 351904792)
15. Schiller JH, Adak S, Feins RH, Keller SM, Fry WA, Livingston RB, Hammond ME, Wolf B, Sabatini L, Jett J, Kohman L and Johnson DH: Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol 19: 448-457, 2001. (Pubitemid 32112858)